Screener
Ocular Therapeutix OCUL EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from Ocular Therapeutix’s reported figures.
The source filing: Ocular Therapeutix’s 10-Q, filed May 5, 2026. Open the filing →
- Filed
- May 5, 2026, 7:28 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-055256
FAQ
- What is Ocular Therapeutix's EBITDA?
- Ocular Therapeutix (OCUL) reported EBITDA of -$92.06M in Q1 2026.
- How has Ocular Therapeutix's EBITDA changed year-over-year?
- Ocular Therapeutix's EBITDA decreased by 46.3% year-over-year, from -$62.94M to -$92.06M.
- What is the long-term trend for Ocular Therapeutix's EBITDA?
- Over 4 years (2021 to 2025), Ocular Therapeutix's EBITDA has grown at a 36.9% compound annual growth rate (CAGR), from -$75.62M to -$265.69M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about Ocular Therapeutix's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude